Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis

@article{Sormani2014TreatmentEO,
  title={Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis},
  author={M. Sormani and D. Arnold and N. De Stefano},
  journal={Annals of Neurology},
  year={2014},
  volume={75}
}
  • M. Sormani, D. Arnold, N. De Stefano
  • Published 2014
  • Medicine
  • Annals of Neurology
    • OBJECTIVE To evaluate the extent to which treatment effect on brain atrophy is able to mediate, at the trial level, the treatment effect on disability progression in relapsing-remitting multiple sclerosis (RRMS). [...] Key MethodMETHODS We collected all published randomized clinical trials in RRMS lasting at least 2 years and including as endpoints disability progression (defined as 6 or 3 months confirmed 1-point increase on the Expanded Disability Status Scale), active magnetic resonance imaging (MRI…Expand Abstract
    View on Wiley
    wholebrainatrophy.com
    202 Citations
    Highly Influential Citations
    5
    Background Citations
    59
    Methods Citations
    10
    Results Citations
    7

    Paper Mentions

    Interventional Clinical Trial
    A Study of Allogeneic Human UC-MSC and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS
    STUDY OBJECTIVES: Primary Objective: Assessment of treatment safety based on incidence of any treatment emergent/treatment associated adverse events prior to discharge and at 1, 3… Expand
    ConditionsMultiple Sclerosis, Relapsing-Remitting
    InterventionBiological, Other
    Novo Cellular Medicine Institute LLP
    February 2015 - February 2017
    Interventional Clinical Trial
    A Study of Autologous Bone Marrow-Derived Mononuclear Stem Cells (BM-MNC) and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS
    STUDY OBJECTIVES: Primary Objective: Assessment of treatment safety based on incidence of any treatment emergent/treatment associated adverse events prior to discharge and at 1, 3… Expand
    ConditionsMultiple Sclerosis, Relapsing-Remitting
    InterventionBiological, Other
    Novo Cellular Medicine Institute LLP
    February 2015 - February 2017
    Interventional Clinical Trial
    A Study of Allogeneic Human UC-MSC and Liberation Therapy (When Associated With CCSVI) in Patients With RRMS
    STUDY OBJECTIVES: Primary Objective: Assessment of treatment safety based on incidence of any treatment emergent/treatment associated adverse events prior to discharge and at 1, 3… Expand
    ConditionsMultiple Sclerosis, Relapsing-Remitting
    InterventionBiological, Other
    Genesis Limited
    February 2015 - February 2017
    Blog Post
    ClinicSpeak: MS phenotypes by MRI
    Multiple Sclerosis Research
    20 September 2014
    Blog Post
    Association between changes in brain atrophy and mobility
    Multiple Sclerosis Research
    19 September 2013
    202 Citations
    Citation Type

    Citation Type

    Reliable measurements of brain atrophy in individual patients with multiple sclerosis
    • 34
    • PDF
    Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis
    • 132
    Multiple sclerosis in 2013: Novel triggers, treatment targets and brain atrophy measures
    • 4
    Biomarkers and Disease Activity in Multiple Sclerosis : A cohort study on patients with clinically isolated syndrome and relapsing remitting multiple sclerosis
    • PDF
    Brain parenchymal fraction in healthy individuals and in clinical follow-up of multiple sclerosis
    • Highly Influenced
    • PDF
    Brain atrophy in multiple sclerosis: therapeutic, cognitive and clinical impact.
    • 14
    • PDF
    Brain MRI Predicts Worsening Multiple Sclerosis Disability over 5 Years in the SUMMIT Study
    • R. Bakshi, B. Healy, +9 authors R. Henry
    • Medicine
    • Journal of neuroimaging : official journal of the American Society of Neuroimaging
    • 2020
    • 2
    Fingolimod effect on brain volume loss independently contributes to its effect on disability
    • 28
    Identification of multiple sclerosis patients at highest risk of cognitive impairment using an integrated brain magnetic resonance imaging assessment approach
    • 18
    Treating relapsing–remitting multiple sclerosis: therapy effects on brain atrophy
    • 32

    References

    SHOWING 1-10 OF 35 REFERENCES
    Treatment effect on brain atrophy correlates with treatment effect on disability in multiple sclerosis
    • 132
    Magnetic resonance imaging as a potential surrogate for relapses in multiple sclerosis: A meta‐analytic approach
    • 207
    Use of the brain parenchymal fraction to measure whole brain atrophy in relapsing-remitting MS
    • 55
    • PDF
    Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes
    • 238
    Association of neocortical volume changes with cognitive deterioration in relapsing-remitting multiple sclerosis.
    • 207
    • PDF
    Surrogate endpoints for EDSS worsening in multiple sclerosis: A meta-analytic approach: Measuring disability in relapsing-remitting MS
    • 28
    Magnetic resonance active lesions as individual-level surrogate for relapses in multiple sclerosis
    • 59
    MRI lesions as a surrogate for relapses in multiple sclerosis: a meta-analysis of randomised trials
    • 190
    MRI metrics as surrogate endpoints for EDSS progression in SPMS patients treated with IFN β-1b
    • 52
    Dehydration confounds the assessment of brain atrophy
    • 144
    • PDF